B. Riley’s Top Biotech Picks Ahead of 3Q26 Earnings Season

Investing.com -- B. Riley analyst Mayank Mamtani has identified top biotech picks heading into third-quarter 2026 earnings season, following the Federal Reserve’s 25 basis point rate hike to 4.00%, its first increase since July 2023. The unanimous 12-0 vote left room for one to two additional hikes before year-end. With the 10-year Treasury at its highest level since 2007, small and mid-cap biotech stocks face a macro-driven drawdown that historically has presented buying opportunities.